Compare Abeona Therapeutics Inc (ABEO) vs MasTec Inc (MTZ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs MasTec Inc — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while MasTec Inc trades at $379.86 (market cap $30.08B). The key difference: MasTec Inc is far larger — about 80.6× Abeona Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| ABEO | MTZ | |
|---|---|---|
Market Cap | $373.32M | $30.08B |
Sector | Health | Technology |
52-Week High | $7.23 | $437.51 |
52-Week Low | $4.17 | $168.24 |
Enterprise Value | $228.22M | $32.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
MTZ trades at $380.63, up 1.93% today, with a neutral technical signal. The stock shows strong fundamental momentum, beating earnings estimates in three consecutive quarters, and holds a record $20.3 billion backlog. Recent news highlights a $1.65 billion acquisition of Superior Group to expand data center infrastructure capabilities, positioning the company for growth in AI-driven demand.
Outlook remains positive with 89% analyst buy ratings and a $476.62 consensus price target, implying 25% upside. Key risks include integration challenges from acquisitions and execution risks on large projects. Revenue growth is supported by infrastructure spending trends, but valuation multiples are elevated relative to industry peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
